Overall, dynamic TILs change evaluation on hematoxylin–eosin slides might perform as a versatile and cost-effective biomarker for breast cancer patients, specifically for HER2-positive and TNBC patients. This evidence concerns the gene ERBB2 and breast carcinoma.